Global Neurology Academy

The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.

For more information about GNA, visit www.globalneurologyacademy.org.

414

LikeLikedUnlike

181-195 of 235

Uncovering Disparities in Teleneurology Utilization Post-Pandemic
On the Frontlines of Multiple Sclerosis
Uncovering Disparities in Teleneurology Utilization Post-Pandemic
- Marisa McGinley, DO
Social Support in Schizophrenia: The Role of Emotional Awareness and Regulation
NeuroFrontiers
Social Support in Schizophrenia: The Role of Emotional Awareness and Regulation
- David Kimhy, PhD
Understanding Schizophrenia: New Insights on Prevalence, Treatment, and Quality of Life
NeuroFrontiers
Understanding Schizophrenia: New Insights on Prevalence, Treatment, and Quality of Life
- Natalie Bareis, PhD, LMSW
Gaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions
NeuroFrontiers
Gaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions
- Natalie Bareis, PhD, LMSW
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
On the Frontlines of Multiple Sclerosis
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
- Glenn Wylie, DPhil
Fatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
NeuroFrontiers
Fatigue in Multiple Sclerosis: Investigating Longitudinal Determinants
advertisement
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiers
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
On the Frontlines of Schizophrenia
Schizophrenia Care: Managing Symptoms with Muscarinic Receptor Agonists
- Steven Paul, MD
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiers
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
- Maxwell H. Levy, MD
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
NeuroFrontiers
Developments in Schizophrenia Care: An Alternative to Dopamine Receptor Blockage
- Steven Paul, MD
Schizophrenia Care: Improving Social Cognition and Motivation
On the Frontlines of Schizophrenia
Schizophrenia Care: Improving Social Cognition and Motivation
- Michael Green, PhD
The Evolving gMG Treatment Landscape
NeuroFrontiers
The Evolving gMG Treatment Landscape
- Henry Kaminski, MD
advertisement
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
NeuroFrontiers
Examining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NeuroFrontiers
Unseen Struggles: Impacts of Homelessness on Women with Schizophrenia
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiers
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy